Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.verified

RYTM

Price:

$55.52

Market Cap:

$3.41B

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesit...[Read more]

Industry

Biotechnology

IPO Date

2017-10-09

Stock Exchange

NASDAQ

Ticker

RYTM

The Enterprise Value as of December 2024 (TTM) for Rhythm Pharmaceuticals, Inc. (RYTM) is 3.37B

According to Rhythm Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 3.37B. This represents a change of 20.92% compared to the average of 2.79B of the last 4 quarters.

Rhythm Pharmaceuticals, Inc. (RYTM) Historical Enterprise Value (quarterly & annually)

How has RYTM Enterprise Value performed in the past?

The mean historical Enterprise Value of Rhythm Pharmaceuticals, Inc. over the last ten years is 881.77M. The current 3.37B Enterprise Value has changed 38.10% with respect to the historical average. Over the past ten years (40 quarters), RYTM's Enterprise Value was at its highest in in the September 2024 quarter at 3.16B. The Enterprise Value was at its lowest in in the June 2016 quarter at 0.

Quarterly (TTM)
Annual

Average

881.77M

Median

636.43M

Minimum

305.74M

Maximum

2.59B

Rhythm Pharmaceuticals, Inc. (RYTM) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Rhythm Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 217.59%

Maximum Annual Enterprise Value = 2.59B

Minimum Annual Increase = -79.63%

Minimum Annual Enterprise Value = 305.74M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20232.59B86.23%
20221.39B217.59%
2021438.31M-63.90%
20201.21B56.15%
2019777.52M-0.81%
2018783.85M123.11%
2017351.33M-29.07%
2016495.34M6.07%
2015467.02M52.75%
2014305.74M-79.63%

Rhythm Pharmaceuticals, Inc. (RYTM) Average Enterprise Value

How has RYTM Enterprise Value performed in the past?

The current Enterprise Value of Rhythm Pharmaceuticals, Inc. (RYTM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

1.47B

5-year avg

1.28B

10-year avg

881.77M

Rhythm Pharmaceuticals, Inc. (RYTM) Enterprise Value vs. Peers

How is RYTM’s Enterprise Value compared to its peers?

Rhythm Pharmaceuticals, Inc.’s Enterprise Value is less than Revolution Medicines, Inc. (7.96B), greater than Akero Therapeutics, Inc. (1.71B), greater than Avidity Biosciences, Inc. (3.35B), greater than Protagonist Therapeutics, Inc. (2.21B), greater than Stoke Therapeutics, Inc. (448.43M), greater than uniQure N.V. (661.18M), greater than Rocket Pharmaceuticals, Inc. (1.22B), greater than Solid Biosciences Inc. (126.94M), greater than MeiraGTx Holdings plc (444.51M), less than Nuvalent, Inc. (5.51B), greater than Ventyx Biosciences, Inc. (109.78M), less than Arcellx, Inc. (4.08B), greater than Cullinan Oncology, Inc. (610.74M), greater than Kiniksa Pharmaceuticals, Ltd. (1.36B), greater than Pliant Therapeutics, Inc. (791.17M), greater than Syndax Pharmaceuticals, Inc. (977.49M), greater than Viridian Therapeutics, Inc. (1.34B), greater than Inozyme Pharma, Inc. (209.48M), greater than Relay Therapeutics, Inc. (597.96M), greater than Black Diamond Therapeutics, Inc. (121.51M), greater than Arvinas, Inc. (1.18B),

Build a custom stock screener for Rhythm Pharmaceuticals, Inc. (RYTM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rhythm Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Rhythm Pharmaceuticals, Inc. (RYTM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Rhythm Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Rhythm Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Rhythm Pharmaceuticals, Inc. (RYTM)?

What is the 3-year average Enterprise Value for Rhythm Pharmaceuticals, Inc. (RYTM)?

What is the 5-year average Enterprise Value for Rhythm Pharmaceuticals, Inc. (RYTM)?

How does the current Enterprise Value for Rhythm Pharmaceuticals, Inc. (RYTM) compare to its historical average?